2023 Annual Summit on Hematologic Cancers: Incorporation of Novel Therapies in Clinical Practice

Nashville, TN US
September 15, 2023 to September 17, 2023

This CME-accredited activity 2023 Annual Summit on Hematologic Cancers features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, multiple myeloma, and lymphoma. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances along with case-based discussion in the field of hematologic malignancies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.

 

SPONSORS:

Platinum Sponsor: Bristol Myers Squibb

Gold Sponsors: Genentech, Janssen Biotech

Bronze Sponsor: Novartis

 

Target Audience

  • Cancer care professionals
  • Practicing medical oncologists/hematologists
  • Radiation oncologists
  • Pathologists
  • Medical oncology and hematology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists

HOTEL RESERVATIONS

A limited number of guestrooms have been reserved at the Gaylord Opryland Hotel for participants of this meeting at the discounted nightly single/double rate of $319/night. Reservations by attendees must be made on or before 5 PM CST on Friday, August 8, 2023, to receive the discounted room rate. Individual Reservations for the Event will be made by individual attendees directly with Marriott reservations at (877) 351-5021.

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
  • Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
  • Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors 
  • Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies
Course summary
Available credit: 
  • 13.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 13.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 13.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 13.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 13.75 Contact Hours.
Course opens: 
01/17/2023
Course expires: 
10/17/2023
Event starts: 
09/15/2023 - 1:30pm PDT
Event ends: 
09/17/2023 - 12:00pm PDT
Cost:
$450.00

Conference chairs: Nitin Jain, MD, Navneet Majhail, MD, MS, Shaji Kumar, MD, & Sonali Smith, MD

All times below are in Central Daylight Time (CDT)

Day 1 - September 15, 2023

Conference Space: General session is in Cheekwood ABC and exhibit hall is in Magnolia Ballroom.

12:00 PM - 01:00 PM: REGISTRATION, EXHIBITS, & SOCIALIZE


01:00 PM - 01:15 PM: OPENING REMARKS - Navneet Majhail, MD, MS

01:15 PM- 01:30 PM: Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


01:30 PM - 03:00 PM: SESSION 1: ALL

Chairs: Lori Muffly, MD, MS & Nitin Jain, MD 

01:30 PM - 01:45 PM: How do I incorporate CAR T in my clinical practice?-  Lori Muffly, MD, MS

01:45 PM - 02:00 PM: Anything new in T-ALL therapy? - Nitin Jain, MD

02:00 PM -03:00 PM: Q & A and Case-Based Panel Discussion- Minoo Battiwalla MD, MS, Lori Muffly, MD, MS & Nitin Jain, MD


03:00 PM – 03:30 PM: BREAKS & EXHIBITS


03:30 PM – 05:00 PM: SESSION 2: AGGRESSIVE LYMPHOMAS

Chairs: Nirav Shah, MD & Sairah Ahmed, MD

03:30 PM - 03:45 PM: Sequencing of CAR-T- Olalekan O. Oluwole, M.B.B.S., M.D.

03:45 PM - 04:00 PM: Focus on elderly patients and CAR-T- Sairah Ahmed, MD

04:00 PM - 05:00 PM: Q & A and Case-Based Discussion Nirav Shah, MD & Sairah Ahmed, MD, Olalekan O. Oluwole, M.B.B.S., M.D., Bhagirathbhai Dholaria, M.D.


05:00 PM - 06:00 PM: ABSTRACT SESSION 

Session Chair: Naveen Pemmaraju, MD

05:00 PM- 05:12 PM: Evaluation of Emergent FLT3 Mutations at Relapse in Patients with Wild-type FLT3 Acute Myeloid Leukemia- Fadi Haddad, MD

05:12 PM - 05:24 PM: A CD5 gene signature identifies diffuse large B-cell lymphomas sensitive to Brutonʼs tyrosine kinase inhibition- Alan Cooper

05:24 PM- 05:36 PM: Prognostic risk signature in patients with newly diagnosed acute myeloid leukemia treated with hypomethylating agents and venetoclax- Alex Bataller, MD, PhD

05:36 PM- 05:48 PM: Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel as an FDA-Approved Standard of Care- Gregory Roloff, MD

05:48 PM- 06:00 PM: Durable Responses in Acute Lymphoblastic Leukemia Using Targeted Therapies Approved for Acute Myeloid Leukemia- Rafael Madero Marroquin, MD   


 

Day 2 - September 16

07:00 AM - 08:00 AM: REGISTRATION, EXHIBITS, & SOCALIZE


08:15 AM – 09:45 AM: SESSION 3: MULTIPLE MYELOMA – NEWLY Dx

Chairs: Muzaffar H. Qazilbash, MD & Noopur Raje, MD

08:15 AM - 08:30 AM: Triplets or quadruplets – what is the right approach for newly diagnosed MM? - Noopur Raje, MD

08:30 AM - 08:45 AM: Transplant for MM – does it still have a role? - Muzaffar H. Qazilbash, MD

08:45 AM - 09:00 AM: Maintenance approaches for MM – one drug or two? - Shaji Kumar, MD

09:00 AM - 09:45 AM: Q & A and Case- Based Discussion- Shuang Fu, MD, PhD, Muzaffar H. Qazilbash, MD, Noopur Raje, MD, Shaji Kumar, MD


09:45 AM – 10:30 AM: BREAKS & EXHIBITS

 

Product Theater Sponsored by Janssen PT

 

Title:  A Treatment for Adult Patients with RRMM who have Received at Least Four prior lines of therapy, including a proteasome inhibitor, an
 immunomodulatory agent and an anti-CD38 monoclonal antibody.

 

Speaker name: Rafat Abonour, MD

 


10:30 AM – 12:00 PM: SESSION 4: AML/MDS

Chairs: Stephen Strickland, MD, MSCIAlexander Perl, MD

10:30 AM - 10:45 AM: Frontline Therapy of AML in 2023 - Tapan Kadia, MD

10:45 AM - 11:00 AM: Updates in treatment of MDS - Hetty Carraway, MD

11:00 AM - 11:20 AM: ICC vs. WHO: Clash of the Titans- Sanam Loghavi, MD

11:20 AM - 12:00 PM: Q & A and Case- Based Discussion- Somedeb Ball, MD, Jonathan A. Abbas, MD, Stephen Strickland, MD, MSCIAlexander Perl, MD, Sanam Loghavi, MD, Hetty Carraway, MD, and Tapan Kadia, MD


12:00 PM - 01:00 PM: LUNCH, EXHIBITS & INDUSTRY SPONSORED SYMPOSIA  

12:00 – 12:45 PM- Product Theater Sponsored by BMS- in Cheekwood F

Title: Treatment Options in Relapsed Refractory Multiple Myeloma: Clinical Data and Patient Cases

A presentation on Relapsed Refractory Multiple Myeloma including disease state overview, clinical trials, and hypothetical patient cases with questions.

Speaker: Kelly McCaul, MD. University of Tennessee Cancer Specialists, Knoxville, TN
 


01:00 PM - 01:30 PM: (KEYNOTE) TREATMENT OF HODGKIN LYMPHOMA IN 2023 - Ranjana H. Advani, MD


01:30 PM - 03:00 PM: SESSION 5: CLL

Chairs: Nitin Jain, MD & Jacqueline Barrientos, MD, MS

01:30 PM - 01:45 PM: BTK or BCL2i or Both for Frontline CLL- Mazyar Shadman, MD, MPH

01:45 PM - 02:00 PM: Pirtobrutinib, CAR T, and others. How to incorporate it in practice?- William Wierda, MD, PhD

02:00 pm - 02:20 PM: Richter transformation. What’s new?- Sameer A Parikh, MBBS

02:20 PM - 03:00 PM: Q & A and Case- Based Discussion Nitin Jain, MD,  Jacqueline Barrientos, MD, MS, Mazyar Shadman, MD, MPH, William Wierda, MD, PhD, Sameer A Parikh, MBBS, Shilpan Shah, MD


03:00 PM – 03:30 PM: BREAKS & EXHIBITS


03:30 PM – 05:00 PM: SESSION 6: LOW-GRADE LYMPHOMAS

Chairs: Sonali Smith, MD & Brian T. Hill, MD, PhD       

03:30 PM - 03:45 PM: Are bi-specifics really going to have a role in indolent lymphomas?- Brian T. Hill, MD, PhD

03:45 PM - 04:00 PM: Sequencing of treatments in 2L+ settings- Loretta Nastoupil, MD

04:00 PM - 05:00 PM: Q & A and Case- Based Panel Discussion Sonali Smith, MD,  Brian T. Hill, MD, PhD, and Loretta Nastoupil, MD


05:00 PM - 6:00 PM: Raise a Toast for Women in Hematology 

**This is a non-CME activity**

Sponsored by Jazz Pharmaceuticals

  • 05:00 PM- 05:15 PM: Career Reflection:  Sonali Smith, MD
  • 05:15 PM- 05:30 PM: Career Reflection: Ishwaria Subbiah, MD, MS
  • 05:30 PM- 06:00 PM: Panel Discussion: Loretta Nastoupil, MD, Sanam Loghavi, MD

Day 3 - September 17

07:00 AM - 08:00 AM: REGISTRATION, EXHIBITS, & SOCIALIZE


Keynote Talk: 

08:15 AM- 08:45 AM:  Precision Medicine in Oncology- Vivek Subbiah, MD


08:45 am - 10:10 AM: SESSION 7: CML/MPN

Chairs: Gabriela Hobbs, MD & Naveen Pemmaraju, MD

08:45 AM - 09:00 AM: Incorporating novel JAKi and other therapies in MF management- Ashwin Kishtagari, MD

09:00 AM - 09:15 AM: Unanswered questions in CML in 2023- Jorge Cortes, MD

09:15 AM - 09:30 AM: Advanced MPN. Unanswered questions- Anand Patel, MD

09:30 AM -10:10 AM: Q & A and Case- Based Discussion- Srinivas Tantravahi, MD, Gabriela Hobbs, MD,  Naveen Pemmaraju, MD, Ashwin Kishtagari, MD, Jorge Cortes, MD, Anand Patel, MD, Kamran M. Mirza, MD PhD


10:10 AM - 10:30 AM: BREAKS & EXHIBITS


10:30 AM - 12:00 PM: SESSION 8: MULTIPLE MYELOMA – R/R

Chairs: Shaji Kumar, MD & Natalie Callander, MD

10:30 AM - 10:45 AM: Management of early relapses in myeloma-choosing the right combination - Natalie Callander, MD

10:45 am - 11:00 AM: Integrating immunotherapies into the treatment of relapsed MM – CART, ADC, and bispecifics - Jesus Berdeja, MD

11:00 AM - 11:15 AM: Non-immune approaches for advanced myeloma - Ajay Nooka, MD, MPH, FACP

11:15 AM - 12:00 PM: Q & A and Case- Based Discussion Shaji Kumar, MD, Natalie Callander, MD, Jesus Berdeja, MD, and Ajay Nooka, MD, MPH, FACP


12:15 PM: ADJOURN

Gaylord Opryland Resort & Convention Center
2800 Opryland Dr
Nashville, TN 37214
United States

The conference will be held in the Magnolia area of the hotel. The exhibitor space is in the Magnolia Ballroom and the general session is in Cheekwood ABC.

Guest room reservation

A limited number of guest rooms have been reserved at the Gaylord Opryland Hotel for participants of this meeting at the discounted nightly single/double rate of $319/night. 

Reservation cut-off: 

Reservations must be made on or before 5 PM CST on Friday, August 8, 2023, to receive the discounted room rate.

Applicable taxes will be added to room rates (currently 9.25% State Tax, 6% Occupancy Tax and $2.50 City Tax). Rates quoted are for single/double occupancy. Each additional person to a room is $20.00. 

Children twelve (12) years and under are free when occupying the same room as their parents. Atrium view upgrades are an additional $60.00.

RESERVATION METHOD:

Reservations must be made directly with Marriott reservations at (877) 351-5021 or follow the link below to receive the discounted rate.

Room reservation Link -   

https://book.passkey.com/go/NashvilleHematology2023

RESORT FEE: The prevailing resort fee, currently $25.00 plus applicable taxes, will be added to the guest room rate. This fee will cover several in-room amenities which at the time of check-in will include: 

  • Resort Wide Internet Access to include: Enhanced in-room wireless Internet Access for up to six (6) devices and Basic Wireless Internet Access in Public Areas and Convention Center on a Shared Network

  • Unlimited local and long-distance calls

  • Daily shuttle service to Opry Mills and The Inn at Opryland

  • Shuttle transportation to scheduled Grand Ole Opry and General Jackson Showboat performances

  • Bottled water (2 daily) replenished once daily with housekeeping service

  • Daily credit of up to $10 per room toward dry cleaning (credit is not cumulative through stay)

  • Transportation to Gaylord Springs Golf Links, practice range access and daily bucket of balls (rental club provided; appropriate attire required)

 

Travel

Parking

The parking fee is currently $33.00 plus tax for self-parking and $45.00 plus tax for valet parking. The hotel will provide $10 off the currently prevailing parking rate to the attendees of the conference. Attendees are responsible for covering the costs of parking themselves.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTEREST:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Course Director(s)

Nitin Jain, MD

has a financial relationship (Gift) with Pharmacyclics;.
has a financial relationship (Gift) with AstraZeneca;.
has a financial relationship (Gift) with Cellectis;.
has a financial relationship (Gift) with Genentech;.
has a financial relationship (Gift) with Beigene;.
has a financial relationship (Gift) with AbbVie;.
has a financial relationship (Gift) with Precision Bio;.
has a financial relationship (Gift) with Janssen;.
has a financial relationship (Gift) with Kite;.
has a financial relationship (Gift) with Fate Therapeutics;.

Shaji Kumar, MD

has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.
has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.

Navneet Majhail, MD, MS, FASTCT

has a financial relationship (Independent contractor) with Anthem Inc;.
has a financial relationship (Independent contractor) with Incyte;.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Sonali Smith, MD FASCO

has a financial relationship (Employment) with Caris Life Sciences ;.
has a financial relationship (Independent contractor) with Ono Pharmaceuticals;.
Speaker/Topic Presenter(s)

Jonathan Abbas, MD

has a financial relationship (Professional Services) with Incyte;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with Genmab;.

Ranjana Advani, Professor of Medicine at Stanford University

has a financial relationship (Other) with Bristol Myers Squibb/Celgene;.
has a financial relationship (Other) with Genentech/Roche;.
has a financial relationship (Financial Support) with Conjupro;.
has a financial relationship (Financial Support) with Cyteir;.
has a financial relationship (Other) with Incyte;.
has a financial relationship (Other) with BeiGene;.
has a financial relationship (Financial Support) with Daiichi;.
has a financial relationship (Other) with Daiichi;.
has a financial relationship (Other) with ADCT;.
has a financial relationship (Financial Support) with Seattle Genetics;.
has a financial relationship (Financial Support) with Gilead;.
has a financial relationship (Other) with Epizyme;.
has a financial relationship (Financial Support) with Regeneron;.
has a financial relationship (Financial Support) with Merck;.

Somedeb Ball, Assistant Professor of Medicine, Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

has no relevant financial relationships to disclose at this time.

Jacqueline Barrientos

has a financial relationship (Other) with Beigene;.
has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Merck;.
has a financial relationship (Other) with Pharmacyclics;.

Alex Bataller, MD PhD

has no relevant financial relationships to disclose at this time.

MINOO BATTIWALLA, MD

has a financial relationship (Financial Stake) with Apellis Pharma;.

Jesus Berdeja

has a financial relationship (Grant Or Contract) with CARsgen;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with Zentalis;.
has a financial relationship (Professional Services) with CRISPR Therapeutics;.
has a financial relationship (Professional Services) with Roche;.
has a financial relationship (Grant Or Contract) with Acetylon;.
has a financial relationship (Grant Or Contract) with C4 Therapeutics;.
has a financial relationship (Grant Or Contract) with Fate Therapeutics;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Professional Services) with Celgene;.
has a financial relationship (Professional Services) with Legend Biotech;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Celularity;.
has a financial relationship (Grant Or Contract) with Ichnos Sciences;.
has a financial relationship (Grant Or Contract) with Sanofi;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Kite Pharma;.
has a financial relationship (Grant Or Contract) with 2Seventy Bio;.
has a financial relationship (Grant Or Contract) with Cartesian Therapeutics;.
has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with Karyopharm;.
has a financial relationship (Professional Services) with Bluebird;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Grant Or Contract) with Amgen;.

Natalie Callander

has no relevant financial relationships to disclose at this time.

Hetty Carraway, MD, MBA

has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Jazz;.
has a financial relationship (Professional Services) with Agios;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Syndax;.
has a financial relationship (Grant Or Contract) with Celegene;.
has a financial relationship (Professional Services) with Gilead;.

Alan Cooper

has no relevant financial relationships to disclose at this time.

Jorge Cortes, MD

has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Sun Pharma;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Other) with Takeda;.

Bhagirathbhai Dholaria, MD

has a financial relationship (Grant Or Contract) with ADC therapeutics;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Travel) with Janssen;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Wugen;.
has a financial relationship (Independent contractor) with MJH bio;.
has a financial relationship (Grant Or Contract) with Angiocrine;.
has a financial relationship (Grant Or Contract) with Arivan;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Grant Or Contract) with MEI;.

Shuang Fu, MD, PhD

has no relevant financial relationships to disclose at this time.

Fadi Haddad

has no relevant financial relationships to disclose at this time.

Brian Hill, MD, PhD

has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Pharmacyclics;.
has a financial relationship (Independent contractor) with Gilead;.
has a financial relationship (Independent contractor) with Genmab;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Independent contractor) with Abbvie;.

Tapan Kadia, MD

has a financial relationship (Grant Or Contract) with DrenBio;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Cellenkos;.
has a financial relationship (Grant Or Contract) with Iterion;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Agios;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Liberum;.
has a financial relationship (Grant Or Contract) with Janssen ;.
has a financial relationship (Grant Or Contract) with DAVA Oncology;.
has a financial relationship (Grant Or Contract) with AbbVie;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Regeneron;.
has a financial relationship (Grant Or Contract) with Sellas;.
has a financial relationship (Grant Or Contract) with Daichi Sankyo;.
has a financial relationship (Grant Or Contract) with Hikma Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Servier;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Genfleet;.
has a financial relationship (Grant Or Contract) with Astex;.
has a financial relationship (Grant Or Contract) with Delta-Fly Pharma;.
has a financial relationship (Grant Or Contract) with Sanofi;.
has a financial relationship (Grant Or Contract) with Ascentage;.
has a financial relationship (Grant Or Contract) with Pulmotech;.
has a financial relationship (Grant Or Contract) with Glycomimetics;.
has a financial relationship (Grant Or Contract) with Jazz Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Rigel;.

Ashwin Kishtagari

has a financial relationship (Professional Services) with Servier pharma ;.
has a financial relationship (Professional Services) with Geron pharma ;.
has a financial relationship (Professional Services) with CTI Biopharma ;.

Sanam Loghavi, Associate Professor

has a financial relationship (Professional Services) with Caris ;.
has a financial relationship (Professional Services) with QualWorld;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Guidepoint;.
has a financial relationship (Professional Services) with Abbvie ;.
has a financial relationship (Professional Services) with OncLive;.
has a financial relationship (Stock) with Abbvie ;.
has a financial relationship (Travel) with Mission Bio ;.
has a financial relationship (Professional Services) with GLG;.

Rafael Madero Marroquin

has no relevant financial relationships to disclose at this time.

Kamran Mirza, MD PhD

has a financial relationship (Independent contractor) with Astellas Pharma;.

Loretta Nastoupil, MD

has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with Regeneron;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.
has a financial relationship (Grant Or Contract) with Gilead/Kite;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Genmab;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Grant Or Contract) with Genentech;.

Ajay Nooka, MD MPH

has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with GSK;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Cellectar;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with K36 therapeutics;.
has a financial relationship (Professional Services) with Janssen Pharmacaeuticals;.
has a financial relationship (Professional Services) with Adaptive biotechnology;.
has a financial relationship (Professional Services) with ONK therapeutics;.

Olalekan Oluwole

has a financial relationship (Professional Services) with Epizyme;.
has a financial relationship (Professional Services) with Cargo;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Nektar;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with ADC;.
has a financial relationship (Professional Services) with Kite;.

Sameer Parikh

has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with AbbVie;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Other) with BeiGene;.
has a financial relationship (Other) with Kite Pharma;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Other) with Novalgen Limited;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Other) with MingSight Pharmaceuticals;.

Anand Patel, Assistant Professor of Medicine; Medical Director, Inpatient Leukemia Service

has a financial relationship (Other) with Bristol Myers Squibb;.
has a financial relationship (Other) with AbbVie;.
has a financial relationship (Grant Or Contract) with Sumitumo;.
has a financial relationship (Grant Or Contract) with Kronos Bio;.
has a financial relationship (Grant Or Contract) with Pfizer;.

Muzaffar Qazilbash

has no relevant financial relationships to disclose at this time.

Noopur Raje, Professor

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Roche;.
has a financial relationship (Professional Services) with GSK;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with K35 Therapeutics;.
has a financial relationship (Professional Services) with 2 Seventy Bio;.

Gregory Roloff

has no relevant financial relationships to disclose at this time.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Employment) with BMS;.

Shilpan Shah

has no relevant financial relationships to disclose at this time.

Vivek Subbiah, MD

has no relevant financial relationships to disclose at this time.

Srinivas Tantravahi, MBBS; MRCP

has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Financial Support) with karyopharm therapeutics;.

William Wierda, MD, PhD

has no relevant financial relationships to disclose at this time.
Moderator(s)

Sairah Ahmed, MD

has a financial relationship (Professional Services) with Chimagen;.
has a financial relationship (Professional Services) with ADCT;.
has a financial relationship (Professional Services) with Tessa ;.
has a financial relationship (Professional Services) with myeloid;.

Gabriela Hobbs, MD

has a financial relationship (Financial Support) with Novartis;.
has a financial relationship (Financial Support) with Cogent;.
has a financial relationship (Financial Support) with Abbvie;.
has a financial relationship (Financial Support) with Pharmaxis;.
has a financial relationship (Financial Support) with BMS;.
has a financial relationship (Financial Support) with Incyte;.
has a financial relationship (Financial Support) with Pfizer;.
has a financial relationship (Financial Support) with Morphosys;.

Lori Muffly

has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Adaptive;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Grant Or Contract) with Jasper;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Independent contractor) with Autolus;.
has a financial relationship (Grant Or Contract) with Kite;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Grant Or Contract) with BMS;.

Naveen Pemmarju

has no relevant financial relationships to disclose at this time.

Alexander Perl, MD

has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Immunogen;.
has a financial relationship (Professional Services) with Foghorn;.
has a financial relationship (Grant Or Contract) with FujiFilm;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Aptose;.
has a financial relationship (Grant Or Contract) with Syndax;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Rigel;.
has a financial relationship (Grant Or Contract) with Astellas;.
has a financial relationship (Professional Services) with Astellas;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.

Noopur Raje, Professor

has a financial relationship (Professional Services) with Roche;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with GSK;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with 2 Seventy Bio;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Professional Services) with K35 Therapeutics;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Pfizer;.

Nirav Shah, MD

has a financial relationship (Independent contractor) with Epizyme;.
has a financial relationship (Independent contractor) with Miltenyi Biotec;.
has a financial relationship (Independent contractor) with BMS-Juno;.
has a financial relationship (Stock) with Tundra Therapeutics;.
has a financial relationship (Independent contractor) with Loxo-Lilly;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with TG Therapeutics;.
has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with Seattle Genetics;.
has a financial relationship (Independent contractor) with Kite;.

Stephen Strickland, MD, MSCI

has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with SentiBio;.
Planning committee(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Commercial Support Acknowledgment

This activity is supported by independent medical education grants from the following companies:

  •  ADC Therapeutics 
  • Novartis Pharmaceuticals Corporation.

Available Credit

  • 13.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 13.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 13.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 13.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 13.75 Contact Hours.

Price

Cost:
$450.00
Please login or register to take this course.

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.